Pegfilgrastim

Generic Name
Pegfilgrastim
Brand Names
Fulphila, Fylnetra, Neulasta, Udenyca, Ziextenzo, Cegfila (previously Pegfilgrastim Mundipharma), Nyvepria, Pelgraz, Grasustek, Pelmeg, Stimufend
Drug Type
Biotech
Chemical Formula
-
CAS Number
208265-92-3
Unique Ingredient Identifier
3A58010674
Background

Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Although the risk of de...

Indication

Pegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non­ myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
...

Associated Conditions
Chemotherapy Induced Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Infection
Associated Therapies
-
Clinical Trials
Related News
mondaq.com
·

Intas Expands Cancer Therapy Biosimilar Portfolio

Intas Pharmaceuticals' U.S. division, Accord BioPharma, acquires Coherus BioSciences' UDENYCA® biosimilar to expand its portfolio. Intas also partners with Xbrane for a nivolumab biosimilar, aiming for launch post-patent expiration.
oncnursingnews.com
·

What's the Difference: Biologics vs Biosimilars in Cancer Care

A near miss incident involving a nurse mistakenly queuing filgrastim instead of pegfilgrastim highlights the challenges in community practice settings with biosimilar usage. Biosimilars, defined by the FDA as highly similar but not identical to reference biologics, have become essential in cancer care due to their lower costs and accelerated FDA approval. Nurses play a crucial role in their administration, verification, and patient education, ensuring the right medication is given to the right patient.
drugstorenews.com
·

Beyond basics

The $134 billion U.S. generic drug industry is diversifying beyond standard generics to boost profits, with companies emphasizing niche products, complex pharmaceuticals, biosimilars, and patient services. Unichem, Amneal, and Somerset Pharma are among those expanding their portfolios and manufacturing capabilities to better respond to market needs and supply challenges. Biosimilars, though costly to develop, offer significant rewards and savings, with companies like Amneal and Dr. Reddy's focusing on this segment.
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy